Dexmedetomidine and propofol
ApprovedSmall molecule
Dexmedetomidine and propofol is one of 39 small molecule programs targeting Arrhythmia. It is currently in Approved.
3
Indications
5
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
43 competitors in Arrhythmia
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsApproved
Betapace
LLegacy Health System
Approved
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Approved
Lanoxin
AAdvanz Pharma
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lovaza
AstraZenecaApproved
Ozempic
Novo NordiskPhase 3
Conventional
PPopulation Health Research Institute
Approved
Rythmol Sr
GGlaxo Dba Glaxosmithkline
Approved
Ancef
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sedation2 trials
Arrhythmia1 trial
Dexmedetomidine1 trial
The Anesthesia Effects of Dexmedetomidine Combined With Desflurane or Propofol in Lobectomy
Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·N/A·NCT06207344·120 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAnesthesia Research Group UA